Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jan 30;14(1):e0210287.
doi: 10.1371/journal.pone.0210287. eCollection 2019.

Factors affecting mortality among HIV positive patients two years after completing recommended therapy for Cryptococcal meningitis in Uganda

Jonathan Kitonsa  1 , Yunia Mayanja  1 , Emmanuel Aling  1 , Julius Kiwanuka  2 , Juliana Namutundu  3 , Zacchaeus Anywaine  1 , Abu-Baker Ggayi  1 , Freddie Kibengo  1 , Noah Kiwanuka  3 , Pontiano Kaleebu  1
Affiliations
Clinical Trial

Factors affecting mortality among HIV positive patients two years after completing recommended therapy for Cryptococcal meningitis in Uganda

Jonathan Kitonsa et al. PLoS One. .

Abstract

Background: Cryptococcal meningitis (CCM) remains a leading cause of mortality amongst HIV infected patients in sub-Saharan Africa. When patients receive recommended therapy, mortality at 10 weeks has been reported to vary between 20 to 36%. However, mortality rate and factors affecting mortality after completing recommended therapy are not well known. We investigated mortality rate, and factors affecting mortality at 2 years among CCM patients following completion of recommended CCM therapy in Uganda.

Methods: A retrospective cohort study was conducted among HIV infected patients that had completed 10 weeks of recommended therapy for CCM (2 weeks of intravenous amphotericin B 1mg/kg and 10 weeks of oral Fluconazole 800mg daily) in the CryptoDex trial (ISRCTN59144167) between 2013 and 2015. Survival analysis applying Cox regression was used to determine the mortality rate and factors affecting mortality at 2 years.

Results: This study followed up 112 participants for 2 years. Mean age (±SD) was 34.9 ± 8, 48 (57.1%) were female and 80 (74.8%) had been on ART for less than 1 year. At 2 years, overall mortality was 30.9% (20 deaths per 100 person-years). Majority of deaths (61.8%) occurred during the first 6 months. In multivariable analysis, mortality was associated with ever being re-admitted since discharge after hospital-based management of CCM (aHR = 13.33, 95% CI: 5.92-30.03), p<0.001; and self-perceived quality of life, with quality of life 50-75% having reduced risk compared to <50% (aHR = 0.21, 95% CI: 0.09-0.5), p<0.001, as well as >75% compared to <50% (HR = 0.29, 95% CI: 0.11-0.81), p = 0.018.

Conclusion: There remains a considerable risk of mortality in the first two years after completion of standard therapy for CCM in resource-limited settings with risk highest during the first 6 months. Maintenance of patient follow up during this period may reduce mortality.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow diagram showing participants enrolled into current study from the CryptoDex trial.
*All patients treated with 1ml/kg of intravenous amphotericin B for 2 weeks and 800mg of oral Fluconazole daily for 10 weeks. **Participants last seen before completion of 2 years.
Fig 2
Fig 2. Kaplan-Meier plot showing survival of participants during two years of follow up after completion of recommended therapy.
See this image and copyright information in PMC

References

    1. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. (2017) Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. The Lancet Infectious Diseases 17: 873–881. 10.1016/S1473-3099(17)30243-8 - DOI - PMC - PubMed
    1. Gordon SB, Walsh AL, Chaponda M, Gordon MA, Soko D, Molyneux ME, et al. (2000) Bacterial Meningitis in Malawian Adults: Pneumococcal Disease is Common, Severe, and Seasonal. Clinical Infectious Diseases 31: 53–57. 10.1086/313910 - DOI - PubMed
    1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525–530. 10.1097/QAD.0b013e328322ffac - DOI - PubMed
    1. Day JN, Chau TTH, Wolbers M, Mai PP, Dung NT, Mai H, et al. (2013) Combination Antifungal Therapy for Cryptococcal Meningitis. New England Journal of Medicine 368: 1291–1302. 10.1056/NEJMoa1110404 - DOI - PMC - PubMed
    1. Kambugu A, Meya DB, Rhein J, O’Brien M, Janoff EN, Ronald AR, et al. (2008) Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral Therapy. Clinical Infectious Diseases 46: 1694–1701. 10.1086/587667 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources